These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 19783244)

  • 1. [Usefulness of urokinase in intraabdominal abscesses].
    García Pérez I; González Vega A
    Cir Esp; 2010 Jul; 88(1):53-4. PubMed ID: 19783244
    [No Abstract]   [Full Text] [Related]  

  • 2. Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat.
    Buyne OR; van Goor H; Bleichrodt RP; Verweij PE; Hendriks T
    Surgery; 2008 Jul; 144(1):66-73. PubMed ID: 18571586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue plasminogen activator for the treatment of intraabdominal abscesses in a neonate.
    Diamond IR; Wales PW; Connolly B; Gerstle T
    J Pediatr Surg; 2003 Aug; 38(8):1234-6. PubMed ID: 12891500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Utility of urokinase in percutaneous drainage treatment of intra-abdominal abscesses].
    Miguelena Bobadilla JM; de Gregorio Ariza MA; Medrano Peña J
    Med Clin (Barc); 2009 Nov; 133(17):662-4. PubMed ID: 19589548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of the thrombolytic efficacy of single-chain urokinase (Pro-urokinase) by heparin.
    Gulba DC; Fischer K; Reil GH; Daniel WG; Lichtlen PR
    Thromb Haemost; 1988 Oct; 60(2):350-1. PubMed ID: 3146150
    [No Abstract]   [Full Text] [Related]  

  • 6. Timing and dose of tissue plasminogen activator to prevent abscess formation after surgical treatment of secondary peritonitis in the rat.
    Buyne OR; van Goor H; Verweij PE; Bleichrodt RP; Hendriks T
    Surg Innov; 2009 Dec; 16(4):299-305. PubMed ID: 20031941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Letter: Urokinase and surgery].
    Contamin C; Denis B; Marty B; Avezou F; Pilichovski P; Guignier M
    Nouv Presse Med; 1974 Sep; 3(32):2024. PubMed ID: 4431708
    [No Abstract]   [Full Text] [Related]  

  • 8. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 9. [First results apropos of 23 observations on the possibilities of fibrinolytic treatment during retinal venous thrombosis].
    Algan B; Henry M; Pierre I; Toussaint M
    Bull Soc Belge Ophtalmol; 1974; 167():585-92. PubMed ID: 4433957
    [No Abstract]   [Full Text] [Related]  

  • 10. [When is fibrinolytic therapy indicated?].
    Woitinas F
    Med Klin; 1980 Feb; 75(3):98-107. PubMed ID: 6990218
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function.
    Wojta J; Binder BR; Huber K; Hoover RL
    Thromb Haemost; 1989 Apr; 61(2):289-93. PubMed ID: 2501899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Principles of therapy with fibrinolytic agents].
    Hiller E
    Fortschr Med; 1986 Aug; 104(30):571-4. PubMed ID: 3093343
    [No Abstract]   [Full Text] [Related]  

  • 13. The CARI guidelines. Evidence for peritonitis treatment and prophylaxis: indications for the use of urokinase in peritoneal dialysis-associated peritonitis.
    Caring for Australians with Renal Impairment (CARI)
    Nephrology (Carlton); 2004 Oct; 9 Suppl 3():S56-8. PubMed ID: 15469559
    [No Abstract]   [Full Text] [Related]  

  • 14. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
    Czyrski J
    Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolytic therapy.
    Duckert F
    Semin Thromb Hemost; 1984 Jan; 10(1):87-103. PubMed ID: 6701539
    [No Abstract]   [Full Text] [Related]  

  • 16. [Fibrinolytic agents in the treatment of venous thrombosis].
    Serradimigni A
    Cardiologia; 1986 Feb; 31(2):85-9. PubMed ID: 3791309
    [No Abstract]   [Full Text] [Related]  

  • 17. [The treatment of cerebrovascular thrombosis and embolism with fibrinolytic agents].
    Araki G
    No To Shinkei; 1992 Sep; 44(9):771-7. PubMed ID: 1476806
    [No Abstract]   [Full Text] [Related]  

  • 18. [Medical treatment of retinal vein thrombosis].
    Algan B
    Bull Soc Belge Ophtalmol; 1982; 201():15-21. PubMed ID: 7187254
    [No Abstract]   [Full Text] [Related]  

  • 19. Thrombolytic agents for acute evolving myocardial infarction: comparative effects.
    Sherry S
    Ration Drug Ther; 1987 Jan; 21(1):1-9. PubMed ID: 3112866
    [No Abstract]   [Full Text] [Related]  

  • 20. [Subacute or chronic thromboembolism of the pulmonary artery. The role of fibrinolytic treatment (apropos of 9 cases)].
    Benaim R; Calvo G; Fischler M; Chiche P
    Ann Med Interne (Paris); 1976 Oct; 127(10):767-70. PubMed ID: 795338
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.